What is Personalis?
Founded in 2011 and headquartered in Menlo Park, California, Personalis operates at the forefront of precision oncology. The company provides sophisticated genomic sequencing and analytic services designed to accelerate the development of personalized cancer vaccines and other immunotherapies. By leveraging cutting-edge technology, Personalis aims to transform cancer treatment paradigms, offering tailored solutions that enhance therapeutic efficacy and patient outcomes. Their work is critical in the evolving landscape of cancer care, where individualized treatment strategies are becoming increasingly vital.
How much funding has Personalis raised?
Personalis has raised a total of $233.5M across 5 funding rounds:
Series A
$20M
Series B
$22M
Series C
$33M
Stock Offering
$140.8M
Stock Offering
$17.7M
Series A (2011): $20M with participation from Lightspeed Venture Partners, Mohr Davidow Ventures, Stanford University, and Abingworth
Series B (2013): $22M led by Lightspeed Venture Partners, Wellington Shields & Co., Mohr Davidow Ventures, and Abingworth
Series C (2015): $33M supported by Abingworth, Mohr Davidow Ventures, and Lightspeed Venture Partners
Stock Issuance/Offering (2019): $140.8M, investors not publicly disclosed
Stock Issuance/Offering (2024): $17.7M backed by Tempus
Key Investors in Personalis
Tempus
Tempus is a technology company focused on AI and machine learning in healthcare, aiming to transform oncology and other medical fields through advanced data analysis and genomic diagnostics. They build large libraries of clinical and molecular data to enable precision-based therapeutic models.
Lightspeed Venture Partners
Lightspeed Venture Partners is a global venture capital firm that invests in early and growth-stage technology companies across various sectors, including enterprise software and infrastructure, from seed stage through IPO.
Abingworth
Abingworth is a transatlantic life sciences investment firm that provides capital and expertise to companies developing novel medicines, focusing on seed, development, and clinical co-development stages.
What's next for Personalis?
The recent major enterprise-level funding signifies a strong vote of confidence in Personalis's technology and market position. This strategic investment is expected to fuel further research and development, enhance operational capacity, and potentially expand the company's market reach. With a clear focus on personalized cancer therapies, Personalis is well-positioned to capitalize on the growing demand for precision medicine, driving innovation in the biotech and healthcare sectors. The company's trajectory suggests a continued focus on scaling its advanced genomic solutions to meet the complex needs of cancer treatment.
See full Personalis company page
